Search results
The Key to Finding Predictive Biomarkers in Metastatic Renal Cell Carcinoma?
MedPage Today· 2 days agoAs Saliby et al. point out in a comprehensive review for the ASCO Educational Book, there are...
David Braun, MD, PhD, on Biomarkers in Renal Cell Carcinoma
MedPage Today· 2 days agoFor patients with metastatic renal cell carcinoma (RCC), there are as yet no reliable biomarkers to...
HCC Screening of At-Risk Adults Improves Detection, Survival
Medscape· 17 hours agoHepatocellular carcinoma screening was associated with earlier detection and improved survival, even...
HUTCHMED begins trial of combination therapy for pancreatic ductal adenocarcinoma
Clinical Trials Arena via Yahoo Finance· 1 day agoIn December last year, Hutchmed finished enrolling subjects in a Phase II/III clinical trial of...
Olympian Maia Shibutani 'Doing Well' After Past Kidney Tumor, Reveals 2024 Olympic Plans (Exclusive)
People via Yahoo Sports· 16 hours ago(SDH)-deficient renal cell carcinoma,” the Olympian wrote on Instagram on Dec. 20, 2019. The tumor...
Leads Biolabs is Proud to Announce its Participation in the 2024 ASCO Annual Meeting with One Oral...
CBS 47 Fresno· 3 days agoThe 2024 American Society of Clinical Oncology (ASCO) Annual Meeting will be held in Chicago from May 31 to June 4, 2024. Leads Biolabs will present the exciting clinical data on its four innovative clinical programs at the ASCO meeting.
HUTCHMED (NASDAQ:HCM) Stock Rating Lowered by StockNews.com
ETF DAILY NEWS· 20 hours agoHUTCHMED (NASDAQ:HCM – Get Free Report) was downgraded by research analysts at StockNews.com from a “buy” rating to a “hold” rating in a research report issued to clients and investors on Monday ...
Iovance (IOVA) Q1 Earnings Surpass, Sales Lag Estimates
Zacks via Yahoo Finance· 5 days agoIovance (IOVA) reports mixed first-quarter results. Shares gain on encouraging initial demand for...
Wedbush Boosts Janux Therapeutics (NASDAQ:JANX) Price Target to $74.00
ETF DAILY NEWS· 5 days agoJanux Therapeutics (NASDAQ:JANX – Free Report) had its target price increased by Wedbush from $53.00 to $74.00 in a research note published on Wednesday morning, Marketbeat reports. The brokerage ...
Billionaire Jim Simons Owns These 2 Healthcare Stocks: Should You?
Motley Fool via Yahoo Finance· 3 days agoIts two most important markets are renal cell carcinoma (RCC, a type of kidney cancer) and...
